CTB-001(Nanjing Bioheng)

N/A

Report date: 2025/02/11 17:16:37

Base Information

Drug NameCTB-001(Nanjing Bioheng)

Drug Alias NameCTB-001CTB001

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CLDN18

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsPancreatic NeoplasmsStomach Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaClinical

Originator CompaniesNanjing Bioheng Biotech Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesNanjing Bioheng Biotech Co Ltd

Inactive CompaniesN/A

Active IndicationsPancreatic NeoplasmsStomach Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A